8-K: AIM ImmunoTech Reports Positive Mid-Year Data for Pancreatic Cancer Drug Ampligen in Combination Study

AIM ImmunoTech Inc. announced encouraging preliminary safety and efficacy results from its Phase 2 DURIPANC study, evaluating Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer.

Summary

• AIM ImmunoTech Inc. reported positive mid-year data from the ongoing Phase 2 DURIPANC clinical study, evaluating Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX.
• The DURIPANC study is an investigator-initiated, exploratory, open-label, single-center study in collaboration with AstraZeneca and Erasmus Medical Center, aiming to enroll up to 25 subjects in Phase 2.
• As of the mid-year report, 14 subjects have been enrolled in the study.
• Preliminary results show no significant toxicity and an encouraging safety profile for the combination therapy.
• Progression-Free Survival (PFS) data indicates that approximately 21% (3 out of 14) of patients had PFS greater than 6 months, with an additional 21% not yet progressed.
• Overall Survival (OS) data shows that 64% (7 out of 11 eligible patients) achieved OS greater than 6 months, which is noted as better than expected in this setting.
• Patient-reported outcomes indicated a consistently high level of quality of life (QoL) throughout the treatment period.
• The company holds a U.S. patent for Ampligen as an oncology treatment in combination with an anti-PD-L1, extending protection to August 9, 2039, and has orphan drug designations for pancreatic cancer in the U.S. and E.U.

Sentiment

Score: 8

Explanation: The filing reports positive preliminary safety and efficacy data for a combination therapy in a highly challenging cancer, exceeding historical expectations for survival metrics. The intellectual property protection further adds to the positive outlook, despite the preliminary nature of the data and small cohort size.

Positives

• The combination therapy of Ampligen and durvalumab demonstrated an encouraging safety profile with no significant toxicity or grade 2 immune-related/systemic toxicities reported.
• Preliminary Progression-Free Survival (PFS) data showed 21% of patients (3/14) had PFS greater than 6 months, with an additional 21% not yet progressed, suggesting promising efficacy.
• Overall Survival (OS) data indicated that 64% (7/11 eligible patients) achieved OS greater than 6 months, which is considered better than expected for metastatic pancreatic cancer in this setting.
• Patient-reported outcomes showed a consistently high level of quality of life (QoL) throughout the treatment period, which is significant for patients with advanced disease.
• The successful completion of the Phase 1 safety study provides a strong foundation for the ongoing Phase 2 trial.
• AIM ImmunoTech has secured intellectual property with a U.S. patent for Ampligen in combination with anti-PD-L1, extending protection to August 9, 2039.
• Orphan drug designations in both the United States and the European Union grant years of market exclusivity for Ampligen post-commercial approval in pancreatic cancer.

Risks

• Data, pre-clinical success, and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in pancreatic cancer.
• Many forward-looking statements involve a number of risks and uncertainties.
• Investors are urged to consider specifically the various risk factors identified in the company's most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K.

Future Outlook

The preliminary data suggests a clear path forward and identifies a promising potential benefit of combining Ampligen's innate immune activation with durvalumab's checkpoint inhibition in pancreatic cancer maintenance therapy. Pending immune-monitoring data analysis is expected to identify additional mechanistic insights or predictive biomarkers, potentially leading to a future therapy for this highly lethal and unmet medical need.

Management Comments

• Prof. Casper van Eijck, MD, PhD, of Erasmus MC, stated: "Our preliminary data suggests that the combination of Ampligen and durvalumab is well-tolerated in post-FOLFIRINOX pancreatic cancer patients, with encouraging preliminary survival data, especially given the historical difficulty of improving outcomes in this setting."
• AIM ImmunoTech CEO Thomas K. Equels stated: "Data from Ampligen as a maintenance monotherapy was extremely positive when compared to existing therapeutic approaches. DURIPANC builds on that foundation and these results suggest a clear path forward and identify a promising potential benefit of combining the selective innate immune activation of Ampligen with the checkpoint inhibition of durvalumab in pancreatic cancer maintenance therapy."
• Thomas K. Equels also expressed hope that "pending immune-monitoring data analysis by Prof. van Eijck and the team at Erasmus Medical Center will identify additional mechanistic insights or predictive biomarkers in this potentially groundbreaking clinical trial, bringing hope for a future therapy for this highly lethal and clearly unmet medical need."

Industry Context

Pancreatic cancer is a highly lethal disease with limited immunotherapy responsiveness, particularly in unselected populations. Historically, maintenance or second-line immunotherapies following FOLFIRINOX chemotherapy have shown limited survival benefit. The positive preliminary results from the DURIPANC study, showing superior PFS and OS compared to historical data and an encouraging safety profile, suggest a potential breakthrough in a field with significant unmet medical need, where over 500,000 people worldwide die each year.

Comparison to Industry Standards

• Compared to the POLO Trial (Olaparib in BRCA-mutated PDAC), which showed a median PFS of 7.4 months vs 3.8 months (placebo) but was applicable to only 5-7% of patients, the DURIPANC study's 21% of patients with PFS >6 months (with an additional 21% not yet progressed) in a broader population is encouraging.
• In contrast to NCT02583477 (Durvalumab + Tremelimumab post-chemotherapy), which showed minimal benefit with a median PFS of less than 2 months and no confirmed responders, the DURIPANC study's preliminary PFS and OS data appear significantly more promising.
• Unlike the IMM-101 trial (NCT01303172), which added immunotherapy to chemo upfront and showed only a modest OS improvement of 2 months without changing the standard of care, the DURIPANC study's OS >6 months in 64% of eligible patients is potentially better than expected in this challenging setting, suggesting a more substantial impact.

Stakeholder Impact

• Shareholders: Potential for increased company valuation due to positive clinical trial results and intellectual property protection for a drug targeting a high unmet medical need.
• Patients: Offers hope for a new, more effective, and well-tolerated treatment option for metastatic pancreatic cancer, a highly lethal disease.
• Medical Community/Researchers: Provides new data and insights into combination immunotherapies for pancreatic cancer, potentially guiding future research and treatment strategies.
• Partners (AstraZeneca, Erasmus MC): Reinforces the value of their collaboration and the potential of their combined therapeutic approaches.

Next Steps

• Conduct immunologic correlatives and further follow-up to determine the biological activity and durability of response.
• Identify which patients are most likely to benefit from the combination treatment to personalize therapy and maximize clinical outcomes.
• Complete immuno-monitoring, including paired tumor biopsies and longitudinal peripheral blood analysis, with results to be reported in the final analysis.
• A final report will follow with complete immunologic analyses and updated survival data.

Key Dates

Recommendation

The preliminary positive safety and efficacy data for Ampligen in combination with Imfinzi for metastatic pancreatic cancer, a disease with historically poor outcomes, represents a significant development. The reported PFS and OS rates are notably better than historical benchmarks, and the favorable safety profile is encouraging. Coupled with the company's intellectual property protection extending to 2039 and orphan drug designations, these results suggest a strong potential for future value creation, warranting a 'buy' recommendation for investors with an appetite for biotech risk, despite the preliminary nature of the data and small cohort size.

Keywords

Pancreatic Cancer, Ampligen, Rintatolimod, Imfinzi, Durvalumab, Phase 2 Clinical Trial, Oncology, Immunotherapy, PD-L1 Inhibitor, TLR3 Agonist, Metastatic Cancer, FOLFIRINOX, DURIPANC Study, Biotechnology, Pharmaceuticals